drug candidate News
-
Onegene Biotechnology selected on a project by Korea Drug Development Fund (KDDF)
KDDF supports development and commercialization of new drug candidates, in order to enhance national competitiveness in new drug R&D ...
-
Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb
Sirenas, LLC ("Sirenas"), a biotechnology company harnessing computational approaches to discover therapeutics derived from the global microbiome, announced today that it has entered into a multi-target research collaboration agreement with Bristol-Myers Squibb to deploy Sirenas' drug discovery platform against certain undisclosed challenging therapeutic targets to identify potential drug ...
By Sirenas
-
Lead drug candidate identified for COVID-19
Kumuda’s platform has identified a method to moderate Coronavirus disease (COVID-19) or effects induced by the SARS-CoV-2 virus by administering to the subject a therapeutically effective amount or application of ACE2 inhibitor or a compound selected from (S,S)-2-[1-carboxy-2-[3[(3,5-dichlorobenzyl)-2H-imidazol-4-yl]-ethylaminol-4-methylpentanoic acid (ORE1001), We have recently applied for ...
By Kumuda
-
Cyrus Biotechnology CEO Lucas Nivon featured in Fierce Biotech Webinar
Date: Thursday, February 3, 2022 Time: 2pm ET / 11am PT Duration: 1 Hour Sign up here to go to the webinar Improving the discovery of novel drugs with artificial intelligence Last year, Toronto-based Deep Genomics used artificial intelligence to scan 200,000 genomes from people with a variety of diseases, and in so doing identified a disease target—Wilson’s—as well ...
-
Lipella Pharmaceuticals Announces Successful Completion of Pre-IND Type B FDA Meeting Regarding Oral Lichen Planus Drug Candidate
Lipella Pharmaceuticals’ LP-310 asset has the potential to become the first oral drug treatment for oral lichen planus Pittsburgh, PA – (May 11, 2021) – Lipella Pharmaceuticals Inc., a clinical stage pharmaceutical company based in Pittsburgh, PA, announced today that the company has successfully concluded a Type B pre-Investigational New Drug (IND) meeting communication with ...
-
BenevolentAI To Present At The 40th Annual JP Morgan Healthcare Conference
London, 07 January, 2022BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that Joanna Shields, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January, 2022 at 8.00am ET / 13.00 GMT. About BenevolentAI BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the ...
By Benevolent
-
Webinar Series
Have a look at INOVOTION’s deeply useful webinar series! Your main preoccupation is optimizing your preclinical and discovery studies? Find out how to use Inovotion’s cutting-edge in vivo technology in your future projects, presented by our experts. #1 How to optimize in vivo preclinical evaluation of synergistic immuni-oncology drug candidate. Speaker:Yan WANG, PhD, MD, R&D Dpt ...
-
NanoTemper Technologies teams up with PharmAI to help researchers spot game-changing drug candidates from millions of possibilities
PharmAI announced a partnership with NanoTemper Technologies, the most innovative producer of biophysical characterization devices. Together, they will zero in on one of the biggest roadblocks to quick drug development: Researchers have to comb through large amounts of data to find the right drug candidates. This process is an innovation killer, making it difficult for small laboratories to do ...
By PharmAI GmbH
-
Cardior Receives EUR 1.01 Million Grant to Identify Novel Oligonucleotides for th e Treatment of Chronic Heart Failure
Hanover, Germany, December 11, 2018 - Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has been granted EUR 1.01 million funding for a joint research project with the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School ...
-
Inovotion Preclinical In Vivo Model
INOVOTION’s high-value preclinical oncology assay quickly identifies your most effective anticancer drug candidates. Our unique technology guarantees fast, reliable, sensitive, and cost-effective results. And it will help you meet the 3Rs guidelines. Learn more and download one of our webinars! Take a step into the future of drug discovery!!! Let’s discover together how ...
-
FRONTBIO Inc IND Approval for Phase 1 Clinical Trial for Eczema Treatment
FRONTBIO, a new drug development bio company, announced on the 5th that it had received approval from the Ministry of Food and Drug Safety on the 2th of last month for a phase 1 clinical trial (IND) for 'FB1A1,' a new drug candidate material under development for the treatment of eczema. FB1A1 treats eczema by normalizing the hypersensitive immune response caused by the imbalance of cytokines ...
By Frontbio
-
Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study
Gesynta Pharma AB today announces the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis - a chronic inflammatory condition affecting approximately 10 percent of all women of reproductive age. This strategically important decision follows a recent preclinical proof-of-concept study with GS-248 in an advanced model of endometriosis, where ...
-
Infant Bacterial Therapeutics receives additional patent protection in China
Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid bacteria, which protects formulations of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of ...
-
TikoMed and IQVIA announce a strategic collaboration for the development of TIKOMED’s lead drug platform candidate ILB®
Today, Swedish biopharmaceutical company TikoMed AB and IQVIA announce a key strategic collaboration with the aim to accelerate the development of TikoMed’s lead drug platform candidate ILB®, a broad-spectrum small molecule drug candidate with curative potential in a wide range of diseases driven by acute and chronic inflammation. The collaboration will support TikoMed’s clinical ...
By TIKOMED AB
-
Symic Bio Announces Last Patient Enrolled in Osteoarthritis Phase 2b Study MODIFY3
DENMARK & SAN FRANCISCO, October 8, 2020 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that the last patient had been enrolled in its Phase 2b OA (osteoarthritis) study. The study, dubbed MODIFY3, is a double-blinded, randomized controlled trial investigating Symic Bio’s DMOAD (diseasemodifying OA drug) candidate, ...
-
Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial
Lipella Pharmaceuticals Inc. said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. The biotechnology company said its next step will be to communicate with the Food and Drug Administration on the study’s results and the pathway forward to seeking regulatory approval ...
-
ImmunogenX Highlighted at Pre-Eminent Celiac Disease Conference
On the basis of clinical success and acknowledged leadership in the field of celiac disease, the organizers of the International Celiac Disease Symposium (ICDS) have invited Jack Syage PhD, CEO of ImmunogenX, to deliver a panel talk and join the Conference Faculty. ICDS is held internationally every other year and is considered the premier conference for celiac disease. This year it will be held ...
-
Confo Therapeutics Enters Collaborative Agreement With Regeneron
Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant conformations, will be ...
-
Bristol Myers Squibb exercises option to develop Exscientia’s AI-designed, immune-modulating drug candidate
First candidate in multi-target collaboration to reach in-license milestone BMS to take responsibility for clinical and commercial development Exscientia receives $20 million option exercise fee with additional development milestones as well as tiered royalties on product sales OXFORD, U.K. – August 18, 2021 – Exscientia, a clinical-stage, artificial intelligence (AI)-driven ...
By Exscientia
-
Optibrium and Lhasa Limited advance predictive modelling for drug-metabolising enzymes
Optibrium and Lhasa Limited publish joint peer-reviewed research in the Journal of Medicinal Chemistry, expanding predictive modelling beyond human Cytochrome P450. Study demonstrates novel predictive models for drug metabolism to improve drug design and Optibrium and Lhasa Limited, two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you